724 related articles for article (PubMed ID: 22940142)
1. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Allen EJ; Palmateer NE; Hutchinson SJ; Cameron S; Goldberg DJ; Taylor A
Int J Drug Policy; 2012 Sep; 23(5):346-52. PubMed ID: 22940142
[TBL] [Abstract][Full Text] [Related]
2. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.
Palmateer N; Hutchinson S; McAllister G; Munro A; Cameron S; Goldberg D; Taylor A
J Viral Hepat; 2014 Jan; 21(1):25-32. PubMed ID: 24329854
[TBL] [Abstract][Full Text] [Related]
3. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
[TBL] [Abstract][Full Text] [Related]
4. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Turner KM; Hutchinson S; Vickerman P; Hope V; Craine N; Palmateer N; May M; Taylor A; De Angelis D; Cameron S; Parry J; Lyons M; Goldberg D; Allen E; Hickman M
Addiction; 2011 Nov; 106(11):1978-88. PubMed ID: 21615585
[TBL] [Abstract][Full Text] [Related]
5. Rapid decline in HCV incidence among people who inject drugs associated with national scale-up in coverage of a combination of harm reduction interventions.
Palmateer NE; Taylor A; Goldberg DJ; Munro A; Aitken C; Shepherd SJ; McAllister G; Gunson R; Hutchinson SJ
PLoS One; 2014; 9(8):e104515. PubMed ID: 25110927
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
[TBL] [Abstract][Full Text] [Related]
7. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011.
Bowring AL; Luhmann N; Pont S; Debaulieu C; Derozier S; Asouab F; Toufik A; van Gemert C; Dietze P; Stoove M
Int J Drug Policy; 2013 Jan; 24(1):78-81. PubMed ID: 23036650
[TBL] [Abstract][Full Text] [Related]
8. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
[TBL] [Abstract][Full Text] [Related]
9. Trends in hepatitis C antibody prevalence among Aboriginal and Torres Strait Islander people attending Australian Needle and Syringe Programs, 1996-2015.
Graham S; Maher L; Wand H; Doyle M; Iversen J
Int J Drug Policy; 2017 Sep; 47():69-76. PubMed ID: 28735774
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
[TBL] [Abstract][Full Text] [Related]
11. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention.
Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L
Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367
[TBL] [Abstract][Full Text] [Related]
12. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
Treloar C; Hull P; Dore GJ; Grebely J
Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
[TBL] [Abstract][Full Text] [Related]
13. Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs.
Palmateer NE; Goldberg DJ; Munro A; Taylor A; Yeung A; Wallace LA; Mitchell A; Shepherd SJ; Gunson RN; Aitken C; Hutchinson SJ
Addiction; 2018 Jan; 113(1):80-90. PubMed ID: 28710874
[TBL] [Abstract][Full Text] [Related]
14. High hepatitis C virus prevalence and incidence in a community cohort of young heroin injectors in a context of extensive harm reduction programmes.
Vallejo F; Barrio G; Brugal MT; Pulido J; Toro C; Sordo L; Espelt A; Bravo MJ;
J Epidemiol Community Health; 2015 Jun; 69(6):599-603. PubMed ID: 25870164
[TBL] [Abstract][Full Text] [Related]
15. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
[TBL] [Abstract][Full Text] [Related]
16. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
[TBL] [Abstract][Full Text] [Related]
17. Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs.
Dunleavy K; Munro A; Roy K; Hutchinson S; Palmateer N; Knox T; Goldberg D; Taylor A
Drug Alcohol Depend; 2017 May; 174():91-97. PubMed ID: 28319754
[TBL] [Abstract][Full Text] [Related]
18. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
19. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
[TBL] [Abstract][Full Text] [Related]
20. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.
Corson S; Greenhalgh D; Taylor A; Palmateer N; Goldberg D; Hutchinson S
Drug Alcohol Depend; 2013 Nov; 133(1):172-9. PubMed ID: 23791029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
